Cost-utility analysis of treatments for advanced non-small cell lung cancer

Rohan Chandrakant Parikh; DR Lairson; Rohan Chandrakant Parikh; JN Cormier; C Wenyaw; XL Du

Cost-utility analysis of treatments for advanced non-small cell lung cancer

Lairson, DR., Parikh, R., Cormier, JN., Wenyaw, C., & Du, XL. (2015). Cost-utility analysis of treatments for advanced non-small cell lung cancer. American Journal of Pharmacy Benefits, 7(6), 271-9. http://www.ajpb.com/journals/ajpb/2015/ajpb_novemberdecember2015/cost-utility-analysis-of-treatments-for-advanced-non-small-cell-lung-cancer

Copy citation

Abstract

Platinum-based chemotherapy may be cost-effective compared with no chemotherapy for the overall elderly population and by age group. However, platinum + targeted therapy was not cost-effective compared with the use of platinum-based therapy alone.

Recent Publications

Article

Treatment preferences among patients with mild-to-moderate atopic dermatitis

December 31, 2023

Article

Understanding how infection prevention influences nurses' task sequencing using a mixed-methods, simulation-based approach

December 01, 2023

Article

Consensus-based framework for evaluating data modernization initiatives

October 01, 2023

Article

∆8-THC-COOH cross-reactivity with cannabinoid immunoassay kits and interference in chromatographic testing methods

September 15, 2023

View All Publications